Cardiovascular Disease

Comorbid chronic diseases common among patients with osteoarthritis, such as obesity, diabetes mellitus and cardiovascular disease, have a significant impact on the progression and persistence of hip osteoarthritis, according to data published in Arthritis Research & Therapy.

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes and nonalcoholic fatty liver disease met its primary endpoint of significant triglyceride lowering.

The FDA issued a safety alert for the weight-loss drug lorcaserin after results from a clinical trial showed it caused a possible increase in cancer risk. It was the week’s top story in endocrinology.

A large cohort of adults with chronic kidney disease, those with prediabetes were more likely to develop proteinuria or experience a cardiovascular event during 7 years of follow-up compared with those with normoglycemia, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Healio and Cardiology Today compiled a list of the most-read articles on updates in diabetes and CVD published in 2019.

The FDA on Thursday approved a new indication for the GLP-1 receptor agonist semaglutide to reduce the risk for major adverse cardiovascular events in adults with type 2 diabetes with known cardiovascular disease, according to a press release from Novo Nordisk.

Among patients with atrial fibrillation, obstructive sleep apnea was an independent risk factor for major adverse CV and neurologic events, particularly stroke, according to findings published in the American Heart Journal.

Adults with diabetes living in Hong Kong, particularly those older than 45 years, saw a drop in mortality due to all-causes, cardiovascular disease and cancer between 2001 and 2016, according to findings published in Diabetologia.

Although the link between climate change and health is “becoming increasingly clear,” the medical community is generally unaware of how much climate change is impacting patients today, experts told Healio Primary Care.

Adults with type 2 diabetes who gain weight after they quit smoking do not decrease their cardiovascular disease risks as much as those who do not gain weight; however, all-cause and cause-specific mortality are similar among quitters who gain or maintain weight, according to findings published in The Lancet Diabetes & Endocrinology.